

ASX Announcement

13 June 2024

PLACEMENT CLEANSING NOTICE

Genetic Signatures Limited (ASX:GSS) (**Company**) advises that it has today issued 8,000,000 fully paid ordinary shares (**Placement Shares**) under the Placement announced on 4 June 2024 to sophisticated and institutional investors at the offer price of \$0.75 per Placement Share. The Placement Shares were issued using the Company's available placement capacity under ASX Listing Rule 7.1.¹

The Company hereby gives notice under section 708A(5)(e) of the Corporations Act (Cth) (**Act**) of the issue of the Placement Shares. The Act restricts the on-sale of securities issued without disclosure unless the sale is exempt under section 708 or 708A of the Act. By the Company giving this notice (**Notice**), a sale of the Placement Shares will fall within the exemption in section 708A(5) of the Act and they will be able to be traded immediately.

For the purposes of section 708A(6) of the Act, the Company gives notice that:

- (a) the Placement Shares were issued without disclosure to investors under Part 6D.2 of the Act;
- (b) this Notice is being given under Section 708A(5)(e) of the Act;
- (c) as at the date of this Notice the Company has complied with:
 - (i) the provisions of Chapter 2M of the Act as they apply to the Company; and
 - (ii) sections 674 and 674A of the Act; and
- (d) as at the date of this Notice there is no excluded information (within the meaning of sections 708A(7) and 708A(8) of the Corporations Act).

-ENDS-

¹ The Company's Listing Rule 7.1 placement capacity was upsized by a Listing Rule 7.1 "supersize" waiver granted by ASX, which allows placement capacity for the Placement to be calculated with the inclusion of shares that may be issued under the underwritten component of the Entitlement Offer.

Authorisation and Additional Information

This announcement was authorised by the Board of Directors of Genetic Signatures Limited.

For further information, see our website www.geneticsignatures.com or contact us as below:

Dr Nick Samaras
Non-Executive
Chairman
investor@geneticsignatures.com

Karl Pechmann
Chief Financial and Operating Officer and
Company Secretary
karl.pechmann@geneticsignatures.com